MedTrace Logo

Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients

NCT01690377 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-12-08

No results posted yet for this study

Summary

Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system. As such they are currently used in clinical vaccination protocols in cancer patients, and both immunological and clinical responses have been observed. Several subsets of dendritic cells have been characterized in the peripheral blood. One such subset is referred to as plasmacytoid dendritic cells (PDC), another as myeloid dendritic cells (myDC). To date PDC and myDC have not been evaluated for their capability to induce anti-tumor immune responses in patients. For this reason the investigators will perform a safety and efficacy study with PDC and myDC in stage IV melanoma patients.

Conditions

Interventions

BIOLOGICAL

PDC or myDC

PDC or myDC; first patient 0.3 \* 10E6 PDC; second and third 1 \* 10E6 PDC; fourth and fifth 3 \* 10E6 PDC.

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • C J A Punt, MD, PhD · Radboud University Medical Center

  • C G Figdor, PhD · Radboud University Nijmegen Medical Centre / Nijmegen Centre for Molecular Life Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01690377 on ClinicalTrials.gov